Pharmaceutical

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

Dec 22, 2023 - 18:00
IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.
Read the original article

Tags:

Previous Article

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Next Article

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pfizer says most tornado damage at key plant hit warehouse, but finished drugs also impacted

STAT+: Pfizer says most tornado damage at key plant hit...

Jul 22, 2023

Gavi to obtain 500,000 mpox vaccine doses from Bavarian Nordic

Gavi to obtain 500,000 mpox vaccine doses from Bavarian...

Sep 20, 2024

An ultrasound device may unlock brain cancer treatment, early study shows

An ultrasound device may unlock brain cancer treatment,...

May 13, 2023